PharmaCyte Biotech (PMCB) Competitors

MiNK Therapeutics (NASDAQ:INKT) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Does the media refer more to INKT or PMCB?

In the previous week, MiNK Therapeutics had 11 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 12 mentions for MiNK Therapeutics and 1 mentions for PharmaCyte Biotech. PharmaCyte Biotech's average media sentiment score of 0.00 beat MiNK Therapeutics' score of -0.45 indicating that PharmaCyte Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
PharmaCyte Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is INKT or PMCB more profitable?

PharmaCyte Biotech's return on equity of 0.76% beat MiNK Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-189.14%
PharmaCyte Biotech	N/A	0.76%	0.45%

Does the MarketBeat Community believe in INKT or PMCB?

MiNK Therapeutics received 17 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.

Company	Underperform	Outperform
MiNK Therapeutics	Outperform Votes 17 77.27%	Underperform Votes 5 22.73%
PharmaCyte Biotech	N/A	N/A

Which has stronger earnings & valuation, INKT or PMCB?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46M	-$2.52	-3.06
PharmaCyte Biotech	N/A	N/A	$330K	$0.74	1.45

Do analysts rate INKT or PMCB?

MiNK Therapeutics presently has a consensus price target of $37.50, indicating a potential upside of 386.07%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe MiNK Therapeutics is more favorable than PharmaCyte Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
PharmaCyte Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals and insiders hold more shares of INKT or PMCB?

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by insiders. Comparatively, 10.2% of PharmaCyte Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more risk and volatility, INKT or PMCB?

MiNK Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.43, meaning that its share price is 143% less volatile than the S&P 500.

Summary

MiNK Therapeutics and PharmaCyte Biotech tied by winning 7 of the 14 factors compared between the two stocks.